Search by Drug Name or NDC
NDC 00169-4181-13 Ozempic 0.68 mg/mL Details
Ozempic 0.68 mg/mL
Ozempic is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novo Nordisk. The primary component is SEMAGLUTIDE.
Product Information
| NDC | 00169-4181 |
|---|---|
| Product ID | 0169-4181_7f4b992f-d010-4e6a-a475-d7133df0ebff |
| Associated GPIs | |
| GCN Sequence Number | 084300 |
| GCN Sequence Number Description | semaglutide PEN INJCTR .25 OR 0.5 SUBCUT |
| HIC3 | C4I |
| HIC3 Description | ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST) |
| GCN | 53536 |
| HICL Sequence Number | 044675 |
| HICL Sequence Number Description | SEMAGLUTIDE |
| Brand/Generic | Brand |
| Proprietary Name | Ozempic |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | semaglutide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 0.68 |
| Active Ingredient Units | mg/mL |
| Substance Name | SEMAGLUTIDE |
| Labeler Name | Novo Nordisk |
| Pharmaceutical Class | GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA209637 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00169-4181-13 (00169418113)
| NDC Package Code | 0169-4181-13 |
|---|---|
| Billing NDC | 00169418113 |
| Package | 1 SYRINGE, PLASTIC in 1 CARTON (0169-4181-13) / 3 mL in 1 SYRINGE, PLASTIC (0169-4181-03) |
| Marketing Start Date | 2022-10-07 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 310.851 |
| Pricing Unit | ML |
| Effective Date | 2024-01-01 |
| NDC Description | OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis